Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematological disorders, cancer and rare immune diseases.

Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

View Press Release View All

Nov 10, 2022 • 4:05pm EST

Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology

Nov 3, 2022 • 4:01pm EDT

Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 3, 2022 • 9:24am EDT

Rigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition

November 2022

View Presentation

American Society of Hematology Annual Meeting and Exposition

View Event View All

Q3 2022

Quarter Ended Sep 30, 2022

Earnings Release

PDF HTML

Audio

Earnings Webcast

Earnings Presentation

PDF

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
1180 Veterans Blvd
South San Francisco, CA 94080